Qiagen Expands With New Deal

摘要

In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen recently entered into two different agreements with U.S. biotech companies—Insight Genetics Inc. and Personal Diagnostics Inc.Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation.